Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Anthocyans on Cardiovascular and Sympathetic Function

This study has been completed.
Sponsor:
Collaborator:
MedPalett
Information provided by:
Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT00634387
First received: March 5, 2008
Last updated: July 3, 2011
Last verified: February 2010
  Purpose

Anthocyans modify cardiovascular and sympathetic function


Condition Intervention
Hypertension
Dietary Supplement: Anthocyans
Other: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Anthocyans on Cardiovascular and Sympathetic Function

Resource links provided by NLM:


Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:
  • Systolic bloodpressure and heartrate [ Designated as safety issue: No ]

Enrollment: 27
Study Start Date: March 2008
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
Anthocyans
Dietary Supplement: Anthocyans
Anthocyans
Dietary Supplement: Anthocyans
Placebo Comparator: B
no effective agent
Dietary Supplement: Anthocyans
Anthocyans
Other: placebo

  Eligibility

Ages Eligible for Study:   35 Years to 50 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ages 35 to 50 years old
  • Males
  • Hypertension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00634387

Locations
Norway
Cardiovascular and Renal Research Center, Ulleval University Hospital
Oslo, Norway, 0407
Sponsors and Collaborators
Ullevaal University Hospital
MedPalett
  More Information

No publications provided

Responsible Party: Morten Rostrup MD PhD, Ullevaal University Hospital
ClinicalTrials.gov Identifier: NCT00634387     History of Changes
Other Study ID Numbers: AC2008
Study First Received: March 5, 2008
Last Updated: July 3, 2011
Health Authority: Norway:National Committee for Medical and Health Research Ethics
Norway: Norwegian Social Science Data Services
Norway: Directorate of Health

Additional relevant MeSH terms:
Hypertension
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on November 25, 2014